Search

Displaying results 4161 - 4170 of 10000 in total
  1. Drug

    Fish oil

    go.drugbank.com/drugs/DB13961
    ApprovedInvestigationalNutraceutical

    Fish oil is a component of SMOFLIPID, which was FDA approved in July 2016. … demonstrated abilities in minimizing or preventing hypertriglyceridemia when taken as an adjunct to a healthy diet [FDA Label].

    Mixtures: OGAMIX(Evening primrose oil 500 mg, Lecithin oil 500 mg, Fish oil 125 mgand Vitamin E 10 mg Soft Gelatin Capsule), SMOFlipid 200 mg/ml Emulsion zur InfusionCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Olopatadine

    go.drugbank.com/drugs/DB00768
    Approved

    It is a structural analog of [doxepin], which has a minimal anti-allergic activity. … [A1172] In comparison to other anti-allergenic ophthalmic medications, olopatadine displays a good comfort and tolerability profile since it does not cause perturbation of cell membranes.

    International brands: Patanol SMixtures: OFNOL FRESH % 0.1 + %0.15 STERİL OFTALMİK ÇÖZELTİ, 1 ADET
  3. Target

    Ribonuclease 4

    go.drugbank.com/bio_entities/BE0001924
    TargetHumans

    Cleaves preferentially after uridine bases (PubMed:3467790). Has antimicrobial activity against uropathogenic E.coli (UPEC) (PubMed:33818125). Probably contributes to urinary tract sterility (PubMed:33818125)

    Polypeptides: Ribonuclease 4Synonyms: RNase 4
  4. Target

    Interleukin-4

    go.drugbank.com/bio_entities/BE0003520
    TargetHumans

    In addition, plays a critical role in higher functions of the normal brain, such as memory and learning (By similarity). … Cytokine secreted primarily by mast cells, T-cells, eosinophils, and basophils that plays a role in regulating antibody production, hematopoiesis and inflammation, and the development of effector T-cell

    Polypeptides: Interleukin-4Synonyms: IL-4
  5. Target

    Caspase-4

    go.drugbank.com/bio_entities/BE0009964
    TargetHumans

    Acts as a thiol protease that cleaves a tetrapeptide after an Asp residue at position P1: catalyzes cleavage of CGAS, GSDMD and IL18 (PubMed:15326478, PubMed:23516580, PubMed:26375003, PubMed:28314590, … Plays a crucial role in the restriction of S.typhimurium replication in colonic epithelial cells during infection (PubMed:25121752, PubMed:25964352).

    Polypeptides: Caspase-4Synonyms: CASP-4
  6. Target

    Myosin-4

    go.drugbank.com/bio_entities/BE0021470
    TargetHumans

    Muscle contraction

    Polypeptides: Myosin-4Synonyms: Myosin heavy chain 4
  7. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    The plasma protein fraction human (PPFh) is defined as a sterile solution of proteins composed mainly of albumin and globulin derived from human plasma. … It is also stated that no more than 1% of the total protein should be gamma globulin.[L2260] PPFh is a sterile, frozen solution of solvent/detergent treated human plasma.

    Mixtures: /ml InfusionslösungProducts: OCTAPLAS Blood Group A, SANDOGLOBULINA 6 G
  8. Drug

    Sumatriptan

    go.drugbank.com/drugs/DB00669
    ApprovedInvestigational

    Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches. … [L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.

    Mixtures: TRASS® TABLETA RECUBIERTA, TRASS® TABLETA RECUBIERTACategories: Monoamine Oxidase A Substrates, P-glycoprotein substrates
  9. Drug

    Spironolactone

    go.drugbank.com/drugs/DB00421
    ApprovedInvestigational

    Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. … [A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]

    Mixtures: Niacinamide 4% / Spironolactone 5%, 011054 Niacinamide 4% / Spironolactone 5%Categories: P-glycoprotein inducers, Cytochrome P-450 CYP2C8 Inhibitors
  10. Drug

    Ibandronate

    go.drugbank.com/drugs/DB00710
    ApprovedInvestigational

    [L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805] … Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].

    Mixtures: IBAMIN D3 150 MG/2800 IU FİLM KAPLI TABLET, 3 ADET, İBAMIN D3 150 MG/2800 IU GRANÜL İÇEREN SAŞE ,3 SAŞEProducts: BONVİVA 3 MG/3 ML ENJEKSİYONLUK ÇÖZELTİ, 4 ADET, ACIDO IBANDRONICO EG